Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274
The proceeds are primarily earmarked for remaining AVERSA Fentanyl clinical development and an FDA marketing-approval application.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nutriband (NTRB) received $1,753,274.53 in proceeds from the exercise of warrants, providing funding for its AVERSA Fentanyl development plans.
A total of 272,671 NTRBW warrants were exercised at $6.43. The warrants expired on September 30 without an extension, leaving no remaining tradeable warrants. Nutriband plans to use the proceeds primarily for remaining clinical development of AVERSA Fentanyl and submission of a new drug application to the FDA for marketing approval. The company cites an estimate that the product could reach $80 million to $200 million in peak annual US sales.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointWarrant exercises provided Nutriband with $1,753,274.53 in proceeds. 2.5% of market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.Nutriband plans to fund remaining AVERSA Fentanyl clinical development and FDA application submission primarily with the proceeds.
- Minor point. Forward-looking: it has not happened yet and may not happen.AVERSA Fentanyl could reach estimated peak annual US sales of $80 million to $200 million.
Negative
- Moderate pointExercise of 272,671 NTRBW warrants at $6.43 dilutes existing shareholders.
Details
Market move: NTRB +7.86% vs previous close. warrant exercise
On Oct 13, the day this news came out, the latest delayed price for NTRB is 7.86% above the previous close. Our momentum scanner has recorded 6 alerts for this stock so far that day. The latest delayed price is $6.31.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Warrants exercised
- 272,671 warrants
- NTRBW warrants
- Exercise price
- $6.43 per warrant
- NTRBW warrant exercise
- Gross proceeds
- $1,753,274.53
- Proceeds to Nutriband from warrant exercises
Previous Offering Reports
-
Raised $5.306 million at $6.43 per warrant for AVERSA development and NDA submission.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nda regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
ORLANDO, Fla., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB), announced today that it has seen 272,671 NTRBW warrants exercised at a strike price of
The primary use of proceeds will be used towards the remaining clinical development of AVERSA Fentanyl and submission of its NDA with the FDA for marketing approval. AVERSA Fentanyl has the potential to become the world's first opioid patch with abuse deterrent properties and is estimated it could reach peak annual US sales of
1 Health Advances Aversa Fentanyl market analysis report 2022
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, including opioids and stimulant drugs, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
SOURCE: Nutriband Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much did Nutriband raise from the NTRBW warrant exercises?
Nutriband received $1,753,274.53 from the exercise of 272,671 NTRBW warrants at a strike price of $6.43. The warrants expired on September 30 without an extension, and the company has no remaining tradeable warrants.
How will Nutriband use the warrant exercise proceeds?
Nutriband plans to use the proceeds primarily for remaining clinical development of AVERSA Fentanyl and submission of a new drug application to the FDA for marketing approval.